Sugi Predict

Sugi Predict / Compounds / SCHEMBL7863859

SCHEMBL7863859

SCHEMBL7863859

Cc1ccc(NC(=O)C2CCC2)cc1

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 1/20 0.66
▸ NPSR1 Q6W5P4 2/20 0.64
▸ LMNA P02545 2/20 0.64
▸ ENPP3 O14638 2/20 0.63
▸ ENPP1 P22413 2/20 0.63
▸ ENPP2 Q13822 2/20 0.63
▸ ALDH1A1 P00352 3/20 0.63
▸ CYP2C19 P33261 1/20 0.63
▸ NAMPT P43490 1/20 0.62
▸ MEN1 O00255 1/20 0.61
▸ KMT2A Q03164 1/20 0.61
▸ HPGD P15428 1/20 0.61
▸ RAB9A P51151 2/20 0.59
▸ KDM4E B2RXH2 1/20 0.59
▸ MAPT P10636 1/20 0.59
▸ PKM P14618 1/20 0.56
▸ POLB P06746 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1339196 0.96 PTPN1 (0.71) PTPN1NPSR1LMNAENPP3ENPP1
SCHEMBL8363734 0.95 PTPN1 (0.74) PTPN1NPSR1LMNAENPP3ENPP1
SCHEMBL7865123 0.92 NAMPT (0.72) PTPN1NPSR1LMNAENPP3ENPP1
Hydrochloric Acid SCHEMBL435505 0.91 NAMPT (0.70) PTPN1NPSR1LMNAENPP3ENPP1
SCHEMBL27383392 0.84 ALDH1A1 (0.58) PTPN1NPSR1LMNAENPP3ENPP1
SCHEMBL13144615 0.84 ALDH1A1 (0.58) NPSR1LMNAENPP3ENPP1ENPP2
SCHEMBL28656982 0.84 PTPN1 (0.89) PTPN1NPSR1LMNAENPP3ENPP1
SCHEMBL125695 0.84 PTPN1 (0.89) PTPN1NPSR1LMNAENPP3ENPP1
SCHEMBL31198189 0.83 PTPN1 (0.68) PTPN1NPSR1LMNAALDH1A1NAMPT
SCHEMBL19302972 0.83 ALDH1A1 (0.69) ALDH1A1CYP2C19NAMPTKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023109883-A1 AROMATIC HETEROCYCLE-SUBSTITUTED COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海翊石医药科技有限公司 2023-06-22 — — WO disclosed
US-20230027295-A1 FXIA INHIBITORS AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) 2023-01-26 — — US disclosed
WO-2021057818-A1 FXIA INHIBITORS AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF 深圳信立泰药业股份有限公司 2021-04-01 — — WO disclosed
US-9200144-B2 Thermoplastic polymer composition MILLIKEN & COMPANY (US) 2015-12-01 — — US disclosed
US-9200142-B2 Thermoplastic polymer composition MILLIKEN & COMPANY (US) 2015-12-01 — — US disclosed
US-9193845-B2 Thermoplastic polymer composition MILLIKEN & COMPANY (US) 2015-11-24 — — US disclosed
US-9120914-B2 Thermoplastic polymer composition MILLIKEN & COMPANY (US) 2015-09-01 — — US disclosed
US-20150094406-A1 THERMOPLASTIC POLYMER COMPOSITION MILLIKEN & COMPANY 2015-04-02 — — US disclosed
US-20150087759-A1 THERMOPLASTIC POLYMER COMPOSITION MILLIKEN & COMPANY 2015-03-26 — — US disclosed
US-20150087757-A1 THERMOPLASTIC POLYMER COMPOSITION MILLIKEN & COMPANY 2015-03-26 — — US disclosed
US-20150087758-A1 THERMOPLASTIC POLYMER COMPOSITION MILLIKEN & COMPANY 2015-03-26 — — US disclosed
US-20120009142-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2012-01-12 — — US disclosed
US-20110268698-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2011-11-03 — — US disclosed
US-7973069-B2 Methods for treating hepatitis C PTC THERAPEUTICS, INC. (US) 2011-07-05 — — US disclosed
US-20100305100-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2010-12-02 — — US disclosed
US-20100305173-A1 HYDROXYETHYLAMINO SULFONAMIDE DERIVATIVES CONCERT PHARMACEUTICALS, INC. (US) 2010-12-02 — — US disclosed
US-20100292187-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2010-11-18 — — US disclosed
WO-2010127272-A2 HYDROXYETHYLAMINO SULFONAMIDE DERIVATIVES CONCERT PHARMACEUTICALS, INC. (US) 2010-11-04 — — WO disclosed
US-20080096928-A9 Indole compounds that modify translational control of Hepatitis C virus PTC THERAPEUTICS, INC. 2008-04-24 — — US disclosed
WO-2007084435-A2 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2007-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230027295-A1 FXIA INHIBITORS AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF F11, TFPI, F7 PTPN1 2370/4885NPSR1 2164/4885LMNA 776/4885
US-20080096928-A9 Indole compounds that modify translational control of Hepatitis C virus EIF2AK2, INMT, IDO1 PTPN1 3969/4885NPSR1 1440/4885LMNA 4373/4885
US-20150087757-A1 THERMOPLASTIC POLYMER COMPOSITION PARG, PUF60, MCM7 PTPN1 3640/4885NPSR1 2794/4885LMNA 347/4885
US-20100305173-A1 HYDROXYETHYLAMINO SULFONAMIDE DERIVATIVES STS, PRSS1, PRSS3 PTPN1 2171/4885NPSR1 2485/4885LMNA 4037/4885
US-20110268698-A1 METHODS FOR TREATING HEPATITIS C HAVCR2, LIPC, HCCS PTPN1 3293/4885NPSR1 2609/4885LMNA 1241/4885
US-20120009142-A1 METHODS FOR TREATING HEPATITIS C OAT, HAVCR2, HCCS PTPN1 4301/4885NPSR1 1853/4885LMNA 3101/4885
US-20100292187-A1 METHODS FOR TREATING HEPATITIS C HAVCR2, EIF2AK2, MAVS PTPN1 3805/4885NPSR1 3320/4885LMNA 1012/4885
US-20100305100-A1 METHODS FOR TREATING HEPATITIS C HAVCR2, EIF2AK2, MAVS PTPN1 3805/4885NPSR1 3320/4885LMNA 1012/4885
US-20150087758-A1 THERMOPLASTIC POLYMER COMPOSITION ERCC4, SMCHD1, XRCC5 PTPN1 2698/4885NPSR1 2618/4885LMNA 855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.